


## PHARMACEUTICAL 2022

## Novan Inc. Rank 287 of 475







## PHARMACEUTICAL 2022

## Novan Inc. Rank 287 of 475



The relative strengths and weaknesses of Novan Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Novan Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Novan Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is -168%, being 109% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	54,130
Cost of Goods Sold	0
Intangible Assets	75
Liabilities, Current	11,150
Liabilities, Non-Current	14,349
Other Assets	2,554
Other Compr. Net Income	0
Other Expenses	114
Other Liabilities	25,142
Other Net Income	223
Property and Equipment	12,201
Research and Development	20,416
Revenues	2,958
Selling, General and Administrative Expense	12,343

Output Variable	Value in 1000 USD
Assets	68,960
Liabilities	50,641
Expenses	32,873
Stockholders Equity	18,319
Net Income	-29,692
Comprehensive Net Income	-29,692
Economic Capital Ratio	-168%

